MNPR
Monopar Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MNPR
Monopar Therapeutics Inc.
A biotech company developing cancer and rare disease treatments in the US
Biological Technology
12/05/2014
12/19/2019
NASDAQ Stock Exchange
14
12-31
Common stock
1000 Skokie Blvd., Suite 350, Wilmette, IL 60091
--
Monopar Therapeutics Inc., originally incorporated in Delaware on December 5, 2014, is a limited liability company and was converted to a C company through a tax-free exchange on December 16, 2015, when the company conducted a 1 for 10 reverse stock split. The company is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients.
Company Financials
EPS
MNPR has released its 2025 Q3 earnings. EPS was reported at -0.48, versus the expected -0.4, missing expectations. The chart below visualizes how MNPR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
